Clinical Data Boehringer advances duo for aggressive cancers into phase 3 PharmaphorumBoehringer Ingelheim steps up its push into oncology with phase 3 trials for pathfinder product Hernexeos and obrixtamig in hard-to-treat cancers.OncologyRead full story pharminent June 22, 2026 (Last updated: June 22, 2026) Pharmaphorum Boehringer Ingelheim steps up its push into oncology with phase 3 trials for pathfinder product Hernexeos and obrixtamig in hard-to-treat cancers. Oncology Read full story Post navigation Previous: Insilico and SK Bio forge $2.5bn AI neuroimmunity allianceNext: Lilly bets up to $800M for BioArctic’s brain delivery tech Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
